APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Amyloidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchAmyloidosis Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyloidosis Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyloidosis Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Amyloidosis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Amyloidosis Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyloidosis Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyloidosis Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Amyloidosis Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Amyloidosis Therapeutics Segment by Company

Pfizer Inc.

GlaxoSmithKline Plc

SOM Innovation Biotech SL

Prothena Corporation Plc

ProteoTech, Inc.

Onyx Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Celgene Corporation

Bsim2

Bellus Health Inc.

Arcturus Therapeutics, Inc

Alnylam Pharmaceuticals, Inc.

Amyloidosis Therapeutics Segment by Type

Canakinumab

CAEL-101

ALN-TTRsc02

ALN-ANG

AG-10

Others

Amyloidosis Therapeutics Segment by Application

ATTR Amyloidoses

AL Amyloidosis

AA Amyloidoses

Others

Amyloidosis Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Amyloidosis Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Amyloidosis Therapeutics Industry Trends Table 2. Amyloidosis Therapeutics Industry Drivers Table 3. Amyloidosis Therapeutics Industry Opportunities and Challenges Table 4. Amyloidosis Therapeutics Industry Restraints Table 5. Global Amyloidosis Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Amyloidosis Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Amyloidosis Therapeutics Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Amyloidosis Therapeutics Sales Market Share by Manufacturers Table 9. Global Amyloidosis Therapeutics Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Amyloidosis Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Amyloidosis Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Amyloidosis Therapeutics Manufacturers, Product Type & Application Table 13. Global Amyloidosis Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Amyloidosis Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Canakinumab Table 17. Major Manufacturers of CAEL-101 Table 18. Major Manufacturers of ALN-TTRsc02 Table 19. Major Manufacturers of ALN-ANG Table 20. Major Manufacturers of AG-10 Table 21. Major Manufacturers of Others Table 22. Global Amyloidosis Therapeutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Amyloidosis Therapeutics Sales by Type (2021-2026) & (k units) Table 24. Global Amyloidosis Therapeutics Sales by Type (2027-2032) & (k units) Table 25. Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2026) Table 26. Global Amyloidosis Therapeutics Sales Market Share by Type (2027-2032) Table 27. Global Amyloidosis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Amyloidosis Therapeutics Revenue by Type (2021-2026) & (k units) Table 29. Global Amyloidosis Therapeutics Revenue by Type (2027-2032) & (k units) Table 30. Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Amyloidosis Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of ATTR Amyloidoses Table 33. Major Manufacturers of AL Amyloidosis Table 34. Major Manufacturers of AA Amyloidoses Table 35. Major Manufacturers of Others Table 36. Global Amyloidosis Therapeutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Amyloidosis Therapeutics Sales by Application (2021-2026) & (k units) Table 38. Global Amyloidosis Therapeutics Sales by Application (2027-2032) & (k units) Table 39. Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2026) Table 40. Global Amyloidosis Therapeutics Sales Market Share by Application (2027-2032) Table 41. Global Amyloidosis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Amyloidosis Therapeutics Revenue by Application (2021-2026) & (k units) Table 43. Global Amyloidosis Therapeutics Revenue by Application (2027-2032) & (k units) Table 44. Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2026) Table 45. Global Amyloidosis Therapeutics Revenue Market Share by Application (2027-2032) Table 46. Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Amyloidosis Therapeutics Sales by Region (2021-2026) & (k units) Table 48. Global Amyloidosis Therapeutics Sales Market Share by Region (2021-2026) Table 49. Global Amyloidosis Therapeutics Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Amyloidosis Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 53. North America Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 54. Europe Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 56. Europe Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Amyloidosis Therapeutics Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Amyloidosis Therapeutics Sales by Country (2027-2032) & (k units) Table 63. Global Amyloidosis Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Amyloidosis Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Amyloidosis Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Amyloidosis Therapeutics Revenue Market Share by Region (2021-2026) Table 67. Global Amyloidosis Therapeutics Revenue Market Share by Region (2027-2032) Table 68. Pfizer Inc. Company Information Table 69. Pfizer Inc. Business Overview Table 70. Pfizer Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Inc. Amyloidosis Therapeutics Product Portfolio Table 72. Pfizer Inc. Recent Development Table 73. GlaxoSmithKline Plc Company Information Table 74. GlaxoSmithKline Plc Business Overview Table 75. GlaxoSmithKline Plc Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio Table 77. GlaxoSmithKline Plc Recent Development Table 78. SOM Innovation Biotech SL Company Information Table 79. SOM Innovation Biotech SL Business Overview Table 80. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio Table 82. SOM Innovation Biotech SL Recent Development Table 83. Prothena Corporation Plc Company Information Table 84. Prothena Corporation Plc Business Overview Table 85. Prothena Corporation Plc Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio Table 87. Prothena Corporation Plc Recent Development Table 88. ProteoTech, Inc. Company Information Table 89. ProteoTech, Inc. Business Overview Table 90. ProteoTech, Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio Table 92. ProteoTech, Inc. Recent Development Table 93. Onyx Pharmaceuticals, Inc. Company Information Table 94. Onyx Pharmaceuticals, Inc. Business Overview Table 95. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 97. Onyx Pharmaceuticals, Inc. Recent Development Table 98. Millennium Pharmaceuticals, Inc. Company Information Table 99. Millennium Pharmaceuticals, Inc. Business Overview Table 100. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 102. Millennium Pharmaceuticals, Inc. Recent Development Table 103. Isis Pharmaceuticals, Inc. Company Information Table 104. Isis Pharmaceuticals, Inc. Business Overview Table 105. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 107. Isis Pharmaceuticals, Inc. Recent Development Table 108. Celgene Corporation Company Information Table 109. Celgene Corporation Business Overview Table 110. Celgene Corporation Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Celgene Corporation Amyloidosis Therapeutics Product Portfolio Table 112. Celgene Corporation Recent Development Table 113. Bsim2 Company Information Table 114. Bsim2 Business Overview Table 115. Bsim2 Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bsim2 Amyloidosis Therapeutics Product Portfolio Table 117. Bsim2 Recent Development Table 118. Bellus Health Inc. Company Information Table 119. Bellus Health Inc. Business Overview Table 120. Bellus Health Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio Table 122. Bellus Health Inc. Recent Development Table 123. Arcturus Therapeutics, Inc Company Information Table 124. Arcturus Therapeutics, Inc Business Overview Table 125. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio Table 127. Arcturus Therapeutics, Inc Recent Development Table 128. Alnylam Pharmaceuticals, Inc. Company Information Table 129. Alnylam Pharmaceuticals, Inc. Business Overview Table 130. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio Table 132. Alnylam Pharmaceuticals, Inc. Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Amyloidosis Therapeutics Distributors List Table 136. Amyloidosis Therapeutics Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Amyloidosis Therapeutics Product Image Figure 2. Global Amyloidosis Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyloidosis Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Amyloidosis Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Amyloidosis Therapeutics Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Amyloidosis Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Canakinumab Image Figure 9. CAEL-101 Image Figure 10. ALN-TTRsc02 Image Figure 11. ALN-ANG Image Figure 12. AG-10 Image Figure 13. Others Image Figure 14. Global Amyloidosis Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Amyloidosis Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2032) Figure 17. Global Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Amyloidosis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. ATTR Amyloidoses Image Figure 21. AL Amyloidosis Image Figure 22. AA Amyloidoses Image Figure 23. Others Image Figure 24. Global Amyloidosis Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Amyloidosis Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2032) Figure 27. Global Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Amyloidosis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032) Figure 30. North America Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Amyloidosis Therapeutics Sales Market Share by Country (2021-2032) Figure 32. U.S. Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Amyloidosis Therapeutics Sales Market Share by Country (2021-2032) Figure 37. Germany Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Country (2021-2032) Figure 44. China Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Country (2021-2032) Figure 52. Brazil Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Amyloidosis Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Amyloidosis Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Amyloidosis Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Figure 63. North America Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Figure 65. Europe Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Amyloidosis Therapeutics Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Amyloidosis Therapeutics Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Amyloidosis Therapeutics Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Canakinumab
  • CAEL-101
  • ALN-TTRsc02
  • ALN-ANG
  • AG-10
  • Others
Applications
  • ATTR Amyloidoses
  • AL Amyloidosis
  • AA Amyloidoses
  • Others
Companies covered
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • SOM Innovation Biotech SL
  • Prothena Corporation Plc
  • ProteoTech, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Celgene Corporation
  • Bsim2
  • Bellus Health Inc.
  • Arcturus Therapeutics, Inc
  • Alnylam Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Amyloidosis Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Amyloidosis Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Amyloidosis Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Amyloidosis Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Amyloidosis Therapeutics Market Dynamics
  1. 2.1 Amyloidosis Therapeutics Industry Trends
  2. 2.2 Amyloidosis Therapeutics Industry Drivers
  3. 2.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Amyloidosis Therapeutics Industry Restraints
3 Amyloidosis Therapeutics Market by Manufacturers
  1. 3.1 Global Amyloidosis Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Amyloidosis Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Amyloidosis Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Amyloidosis Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Amyloidosis Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Amyloidosis Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global Amyloidosis Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Amyloidosis Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Amyloidosis Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
4 Amyloidosis Therapeutics Market by Type
  1. 4.1 Amyloidosis Therapeutics Type Introduction
  2. 4.1.1 Canakinumab
  3. 4.1.2 CAEL-101
  4. 4.1.3 ALN-TTRsc02
  5. 4.1.4 ALN-ANG
  6. 4.1.5 AG-10
  7. 4.1.6 Others
  8. 4.2 Global Amyloidosis Therapeutics Sales by Type
  9. 4.2.1 Global Amyloidosis Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Amyloidosis Therapeutics Sales by Type (2021-2032)
  11. 4.2.3 Global Amyloidosis Therapeutics Sales Market Share by Type (2021-2032)
  12. 4.3 Global Amyloidosis Therapeutics Revenue by Type
  13. 4.3.1 Global Amyloidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Amyloidosis Therapeutics Revenue by Type (2021-2032)
  15. 4.3.3 Global Amyloidosis Therapeutics Revenue Market Share by Type (2021-2032)
5 Amyloidosis Therapeutics Market by Application
  1. 5.1 Amyloidosis Therapeutics Application Introduction
  2. 5.1.1 ATTR Amyloidoses
  3. 5.1.2 AL Amyloidosis
  4. 5.1.3 AA Amyloidoses
  5. 5.1.4 Others
  6. 5.2 Global Amyloidosis Therapeutics Sales by Application
  7. 5.2.1 Global Amyloidosis Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Amyloidosis Therapeutics Sales by Application (2021-2032)
  9. 5.2.3 Global Amyloidosis Therapeutics Sales Market Share by Application (2021-2032)
  10. 5.3 Global Amyloidosis Therapeutics Revenue by Application
  11. 5.3.1 Global Amyloidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Amyloidosis Therapeutics Revenue by Application (2021-2032)
  13. 5.3.3 Global Amyloidosis Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Amyloidosis Therapeutics Sales by Region
  1. 6.1 Global Amyloidosis Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Amyloidosis Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Amyloidosis Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global Amyloidosis Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Amyloidosis Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Amyloidosis Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Amyloidosis Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Amyloidosis Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Amyloidosis Therapeutics Revenue by Region
  1. 7.1 Global Amyloidosis Therapeutics Revenue by Region
  2. 7.1.1 Global Amyloidosis Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Amyloidosis Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Amyloidosis Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Amyloidosis Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Amyloidosis Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Amyloidosis Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Amyloidosis Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Amyloidosis Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Amyloidosis Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc.
  2. 8.1.1 Pfizer Inc. Company Information
  3. 8.1.2 Pfizer Inc. Business Overview
  4. 8.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
  6. 8.1.5 Pfizer Inc. Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 SOM Innovation Biotech SL
  14. 8.3.1 SOM Innovation Biotech SL Company Information
  15. 8.3.2 SOM Innovation Biotech SL Business Overview
  16. 8.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
  18. 8.3.5 SOM Innovation Biotech SL Recent Developments
  19. 8.4 Prothena Corporation Plc
  20. 8.4.1 Prothena Corporation Plc Company Information
  21. 8.4.2 Prothena Corporation Plc Business Overview
  22. 8.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
  24. 8.4.5 Prothena Corporation Plc Recent Developments
  25. 8.5 ProteoTech, Inc.
  26. 8.5.1 ProteoTech, Inc. Company Information
  27. 8.5.2 ProteoTech, Inc. Business Overview
  28. 8.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
  30. 8.5.5 ProteoTech, Inc. Recent Developments
  31. 8.6 Onyx Pharmaceuticals, Inc.
  32. 8.6.1 Onyx Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Onyx Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  36. 8.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Millennium Pharmaceuticals, Inc.
  38. 8.7.1 Millennium Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Millennium Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  42. 8.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Isis Pharmaceuticals, Inc.
  44. 8.8.1 Isis Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Isis Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  48. 8.8.5 Isis Pharmaceuticals, Inc. Recent Developments
  49. 8.9 Celgene Corporation
  50. 8.9.1 Celgene Corporation Company Information
  51. 8.9.2 Celgene Corporation Business Overview
  52. 8.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
  54. 8.9.5 Celgene Corporation Recent Developments
  55. 8.10 Bsim2
  56. 8.10.1 Bsim2 Company Information
  57. 8.10.2 Bsim2 Business Overview
  58. 8.10.3 Bsim2 Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
  60. 8.10.5 Bsim2 Recent Developments
  61. 8.11 Bellus Health Inc.
  62. 8.11.1 Bellus Health Inc. Company Information
  63. 8.11.2 Bellus Health Inc. Business Overview
  64. 8.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
  66. 8.11.5 Bellus Health Inc. Recent Developments
  67. 8.12 Arcturus Therapeutics, Inc
  68. 8.12.1 Arcturus Therapeutics, Inc Company Information
  69. 8.12.2 Arcturus Therapeutics, Inc Business Overview
  70. 8.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
  72. 8.12.5 Arcturus Therapeutics, Inc Recent Developments
  73. 8.13 Alnylam Pharmaceuticals, Inc.
  74. 8.13.1 Alnylam Pharmaceuticals, Inc. Company Information
  75. 8.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
  78. 8.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Amyloidosis Therapeutics Value Chain Analysis
  2. 9.1.1 Amyloidosis Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Amyloidosis Therapeutics Production Mode & Process
  6. 9.2 Amyloidosis Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Amyloidosis Therapeutics Distributors
  9. 9.2.3 Amyloidosis Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst